ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS Russian patent published in 2019 - IPC A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and concerns a method of treating a human patient having FOLR1-expressing cancer, comprising administering to a patient an immunoconjugate that binds to a FOLR1 polypeptide, wherein said immunoconjugate comprises an antibody or an antigen-binding fragment thereof, comprising a variable light chain (VL) CDR-1 according to SEQ ID NO: 6, CDR-2 VL according to SEQ ID NO: 7, CDR-3 VL according to SEQ ID NO: 8, heavy chain variable region (VH) CDR-1 sequence according to SEQ ID NO: 9, CDR-2 VH according to SEQ ID NO: 11, CDR-3 VH according to SEQ ID NO: 12 and maytansinoid. Said immunoconjugate is administered in dose of 6 milligrams (mg) per kilogram (kg) of the adjusted ideal body weight (AIBW) of the patient. Group of inventions also relates to use of said immunoconjugate, which binds to FOLR1 polypeptide, to obtain a pharmaceutical composition for treating FOLR1-expressing cancer; method of treating a human patient having FOLR1-expressing cancer, comprising administering to a patient a composition comprising immunoconjugates, which bind to FOLR1 polypeptide, wherein said immunoconjugates contain on average 3–4 maytansinoid DM4 per antibody.

EFFECT: group of inventions provides prevention of ophthalmic toxicity.

96 cl, 6 ex, 12 dwg, 3 tbl